Drugs Aging. 1996 Jul;9(1):60-5; discussion 66-7. doi: 10.2165/00002512-199609010-00006.


Galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of Alzheimer's disease. Galanthamine is selective for acetylcholinesterase versus butyrylcholinesterase; however, the drug produces greater enzyme inhibition in human erythrocytes than in human brain tissue. Galanthamine attenuates drug-and lesion-induced cognitive deficits in animal models of learning and memory. Preliminary results in patients with Alzheimer's disease have reported galanthamine to be associated with a reduction in cognitive deterioration on some neuropsychiatric rating scales. Nausea and vomiting are the most commonly reported adverse effects; liver toxicity has not been reported to date.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy
  • Animals
  • Cholinesterase Inhibitors* / adverse effects
  • Cholinesterase Inhibitors* / pharmacokinetics
  • Cholinesterase Inhibitors* / pharmacology
  • Clinical Trials as Topic
  • Galantamine* / adverse effects
  • Galantamine* / pharmacokinetics
  • Galantamine* / pharmacology
  • Humans


  • Cholinesterase Inhibitors
  • Galantamine